Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (29457)	11/22/1999 7:26:00 PM
From: Gregory Rasp	Read Replies (1) \| Respond to of 32384

There are 1000 cases or so of CTCL in the US per year. I think that the FDA will be more lenient on a drug to treat an incurable rare disease than it would be on a drug to treat a curable common disease. But I would get more excited if LGND would target a disease with more growth potential. GR

To: tuck who wrote (29457)	11/23/1999 6:50:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

More info on the FDA advisory meeting on Targretin is at: verity.fda.gov (need to copy and paste URL if viewing with earlier version of SI) FDA Advisory Committee Information Line 1-800-741-8138 (301-443-0572 Washington, DC area) Code #12542 Please Call the information line for up-to-date information on this meeting. Earlier meetings are at: verity.fda.gov